Hemocue Urine Albumin Point-Of-Care Test Shows Strong Agreement With the Results Obtained With a Large Nephelometer
- Gösta Florvall1,
- Samar Basu, PHD2,
- Johanna Helmersson, PHD2 and
- Anders Larsson, MD, PHD1
- 1Section of Clinical Chemistry, Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
- 2Section of Clinical Nutrition Research, Department of Public Health and Caring Sciences, Uppsala University Hospital, Uppsala, Sweden
- Address correspondence and reprint requests to Anders Larsson, Department of Medical Sciences, University Hospital, S-751 85 Uppsala, Sweden. E-mail: anders.larsson{at}akademiska.se
There is an increasing incidence of diabetic nephropathy, predominantly in patients with type 2 diabetes (1–3). Persistent microalbuminuria is a sign of ongoing glomerular injury and a strong predictor of clinical nephropathy, and screening for microalbuminuria, the earliest manifestation of diabetic nephropathy, is recommended for all diabetic patients (4).
Point-of-care testing (POCT) offers rapid test results, which facilitate the use of the results to motivate the patient to lifestyle changes and increased compliance (5–7). To achieve good compliance, it is essential that the patient and physician work together and that the patient get regular feedback on the treatment results. The feedback is considered to be more effective if the test results are available during the consultation. This has led to the development of POCT instruments for measuring urine albumin excretion.
The aim of the present study was to evaluate urine albumin analyzed by the HemoCue POCT instrument, …
